The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Fibrosing interstitial lung diseases: knowns and unknowns
Open accessAbstract
Patients with certain types of fibrosing interstitial lung disease (ILD) are at risk of developing a progressive phenotype characterised by self-sustaining fibrosis, decline in lung function, worsening quality of life, and early mortality. It has been proposed that such progressive fibrosing ILDs, which show commonalities in clinical behaviour and in the pathogenetic mechanisms that drive progressive fibrosis, may be “lumped” together for the purposes of clinical research and, potentially, for treatment. At present, no drugs are approved for the treatment of ILDs other than nintedanib and pirfenidone for the treatment of idiopathic pulmonary fibrosis. For other progressive fibrosing ILDs, the mainstay of drug therapy is immunosuppression. However, it is postulated that, once the response to lung injury in fibrosing ILDs has reached the stage at which fibrosis has become progressive and self-sustaining, targeted antifibrotic therapy would be required to slow disease progression. Nintedanib, an intracellular inhibitor of tyrosine kinases, has shown antifibrotic, anti-inflammatory and vascular remodelling effects in several non-clinical models of fibrosis, irrespective of the trigger for the injury. Ongoing clinical trials will provide insight into the role of antifibrotic treatment with nintedanib or pirfenidone in the management of fibrosing ILDs with a progressive phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationTravis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,290
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationTyndall, A. J., Bannert, B., Vonk, M., Airò, P., Cozzi, F., Carreira, P. E., Bancel, D. F., Allanore, Y., Müller-Ladner, U., Distler, O., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.114264 · Cited by 1,443
Interstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,230
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Update of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Fischer, A., Antoniou, K. M., Brown, K. K., Cadranel, J., Corte, T. J., du Bois, R. M., Lee, J. S., Leslie, K. O., Lynch, D. A., Matteson, E. L., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00150-2015 · Cited by 1,099
Self-citationTashkin, D. P., Roth, M. D., Clements, P. J., Furst, D. E., Khanna, D., Kleerup, E. C., Goldin, J., Arriola, E., Volkmann, E. R., Kafaja, S., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30152-7 · Cited by 1,078
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationHoyles, R. K., Ellis, R. W., Wellsbury, J., Lees, B., Newlands, P., Goh, N. S. L., Roberts, C., Desai, S., Herrick, A. L., McHugh, N. J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22204 · Cited by 732
Mapping and predicting mortality from systemic sclerosis
Elhai, M., Meune, C., Boubaya, M., Avouac, J., Hachulla, E., Balbir-Gurman, A., Riemekasten, G., Airò, P., Joven, B., Vettori, S., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211448 · Cited by 691
Turesson, C., O'Fallon, W. M., Crowson, C. S., Gabriel, S. E., & Matteson, E. L. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.8.722 · Cited by 672
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Self-citationKowal-Bielecka, O., Landewé, R., Avouac, J., Chwiesko, S., Miniati, I., Czirjak, L., Clements, P., Denton, C., Farge, D., Fligelstone, K., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.096677 · Cited by 619
Rheumatoid Arthritis–Interstitial Lung Disease–associated Mortality
Olson, A. L., Swigris, J. J., Sprunger, D. B., Fischer, A., Fernandez-Perez, E. R., Solomon, J., Murphy, J., Cohen, M., Raghu, G., & Brown, K. K. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201004-0622oc · Cited by 544
Self-citationdu Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527
MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
Juge, P.-A., Lee, J. S., Ebstein, E., Furukawa, H., Dobrinskikh, E., Gazal, S., Kannengiesser, C., Ottaviani, S., Oka, S., Tohma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801562 · Cited by 520
Self-citationNatsuizaka, M., Chiba, H., Kuronuma, K., Otsuka, M., Kudo, K., Mori, M., Bando, M., Sugiyama, Y., & Takahashi, H. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0566oc · Cited by 502
Interstitial lung disease in polymyositis and dermatomyositis
Marie, I., Hachulla, E., Chérin, P., Dominique, S., Hatron, P. ‐., Hellot, M. ‐., Devulder, B., Herson, S., Levesque, H., & Courtois, H. (2002) · Arthritis Care & Research · doi:10.1002/art.10794 · Cited by 478
Hypersensitivity Pneumonitis: Insights in Diagnosis and Pathobiology
Selman, M., Pardo, A., & King, T. E. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201203-0513ci · Cited by 478
Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.02.001 · Cited by 463
Self-citationWalsh, S. L. F., Wells, A. U., Desai, S. R., Poletti, V., Piciucchi, S., Dubini, A., Nunes, H., Valeyre, D., Brillet, P. Y., Kambouchner, M., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30033-9 · Cited by 458
Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management
Vasakova, M., Morell, F., Walsh, S., Leslie, K., & Raghu, G. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201611-2201pp · Cited by 456
Morell, F., Villar, A., Montero, M.-Á., Muñoz, X., Colby, T. V., Pipvath, S., Cruz, M.-J., & Raghu, G. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70191-7 · Cited by 392
Fernández Pérez, E. R., Swigris, J. J., Forssén, A. V., Tourin, O., Solomon, J. J., Huie, T. J., Olson, A. L., & Brown, K. K. (2013) · Chest · doi:10.1378/chest.12-2685 · Cited by 389
Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease
Solomon, J. J., Chung, J. H., Cosgrove, G. P., Demoruelle, M. K., Fernandez-Perez, E. R., Fischer, A., Frankel, S. K., Hobbs, S. B., Huie, T. J., Ketzer, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00357-2015 · Cited by 388
Self-citationWhat's in a name? That which we call IPF, by any other name would act the same
Wells, A. U., Brown, K. K., Flaherty, K. R., Kolb, M., & Thannickal, V. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.00692-2018 · Cited by 352
Prevalence and prognosis of unclassifiable interstitial lung disease
Ryerson, C. J., Urbania, T. H., Richeldi, L., Mooney, J. J., Lee, J. S., Jones, K. D., Elicker, B. M., Koth, L. L., King, T. E., Wolters, P. J., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00131912 · Cited by 310
The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease
Spagnolo, P., Lee, J. S., Sverzellati, N., Rossi, G., & Cottin, V. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40574 · Cited by 306
Self-citationLey, B., Newton, C. A., Arnould, I., Elicker, B. M., Henry, T. S., Vittinghoff, E., Golden, J. A., Jones, K. D., Batra, K., Torrealba, J., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30216-3 · Cited by 296
Solomon, J. J., Olson, A. L., Fischer, A., Bull, T., Brown, K. K., & Raghu, G. (2013) · European Respiratory Review · doi:10.1183/09059180.00005512 · Cited by 294
Self-citationCharacterisation of patients with interstitial pneumonia with autoimmune features
Oldham, J. M., Adegunsoye, A., Valenzi, E., Lee, C., Witt, L., Chen, L., Husain, A. N., Montner, S., Chung, J. H., Cottin, V., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01565-2015 · Cited by 275
Self-citationJaeger, V. K., Wirz, E. G., Allanore, Y., Rossbach, P., Riemekasten, G., Hachulla, E., Distler, O., Airò, P., Carreira, P. E., Balbir Gurman, A., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163894 · Cited by 268
Hostettler, K. E., Zhong, J., Papakonstantinou, E., Karakiulakis, G., Tamm, M., Seidel, P., Sun, Q., Mandal, J., Lardinois, D., Lambers, C., et al. (2014) · Respiratory Research · doi:10.1186/s12931-014-0157-3 · Cited by 258
Sircar, G., Goswami, R. P., Sircar, D., Ghosh, A., & Ghosh, P. (2018) · Rheumatology · doi:10.1093/rheumatology/key213 · Cited by 246
Morisset, J., Johannson, K. A., Vittinghoff, E., Aravena, C., Elicker, B. M., Jones, K. D., Fell, C. D., Manganas, H., Dubé, B.-P., Wolters, P. J., et al. (2017) · CHEST · doi:10.1016/j.chest.2016.10.029 · Cited by 243
Salisbury, M. L., Myers, J. L., Belloli, E. A., Kazerooni, E. A., Martinez, F. J., & Flaherty, K. R. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1675pp · Cited by 243
The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis
Vourlekis, J. S., Schwarz, M. I., Cherniack, R. M., Curran-Everett, D., Cool, C. D., Tuder, R. M., King, T. E., & Brown, K. K. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.030 · Cited by 241
Progressive Decline of Lung Function in Rheumatoid Arthritis–Associated Interstitial Lung Disease
Zamora‐Legoff, J. A., Krause, M. L., Crowson, C. S., Ryu, J. H., & Matteson, E. L. (2017) · Arthritis & Rheumatology · doi:10.1002/art.39971 · Cited by 215
Huang, J., Beyer, C., Palumbo-Zerr, K., Zhang, Y., Ramming, A., Distler, A., Gelse, K., Distler, O., Schett, G., Wollin, L., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-207109 · Cited by 196
Self-citationPredictors of mortality in rheumatoid arthritis‐related interstitial lung disease
Assayag, D., Lubin, M., Lee, J. S., King, T. E., Collard, H. R., & Ryerson, C. J. (2014) · Respirology · doi:10.1111/resp.12234 · Cited by 195
Paterniti, M. O., Bi, Y., Rekić, D., Wang, Y., Karimi-Shah, B. A., & Chowdhury, B. A. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201606-458oc · Cited by 194
Idiopathic inflammatory myopathies and the lung
Lega, J.-C., Reynaud, Q., Belot, A., Fabien, N., Durieu, I., & Cottin, V. (2015) · European Respiratory Review · doi:10.1183/16000617.00002015 · Cited by 190
Self-citationFlaherty, K. R., Brown, K. K., Wells, A. U., Clerisme-Beaty, E., Collard, H. R., Cottin, V., Devaraj, A., Inoue, Y., Le Maulf, F., Richeldi, L., et al. (2017) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2017-000212 · Cited by 184
Self-citationHuang, J., Maier, C., Zhang, Y., Soare, A., Dees, C., Beyer, C., Harre, U., Chen, C.-W., Distler, O., Schett, G., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210823 · Cited by 182
Self-citationNathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Glasscock, K. F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207011 · Cited by 180
Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2152oc · Cited by 178
Wang, P., Jones, K. D., Urisman, A., Elicker, B. M., Urbania, T., Johannson, K. A., Assayag, D., Lee, J., Wolters, P. J., Collard, H. R., et al. (2017) · Chest · doi:10.1016/j.chest.2017.02.011 · Cited by 165
Pulmonary Fibrosis in Sarcoidosis. Clinical Features and Outcomes
Patterson, K. C., & Strek, M. E. (2013) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201303-069fr · Cited by 147
Effects of nintedanib on the microvascular architecture in a lung fibrosis model
Ackermann, M., Kim, Y. O., Wagner, W. L., Schuppan, D., Valenzuela, C. D., Mentzer, S. J., Kreuz, S., Stiller, D., Wollin, L., & Konerding, M. A. (2017) · Angiogenesis · doi:10.1007/s10456-017-9543-z · Cited by 141
Self-citationŞahin, H., Brown, K. M., Curran‐Everett, D., Hale, V., Cool, C. D., Vourlekis, J. S., & Lynch, D. A. (2007) · Radiology · doi:10.1148/radiol.2442060640 · Cited by 135
Nannini, C., Jebakumar, A. J., Crowson, C. S., Ryu, J. H., & Matteson, E. L. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003569 · Cited by 134
Idiopathic non‐specific interstitial pneumonia
Belloli, E. A., Beckford, R., Hadley, R. J., & Flaherty, K. R. (2015) · Respirology · doi:10.1111/resp.12674 · Cited by 125
Hilberg, F., Tontsch-Grunt, U., Baum, A., Le, A. T., Doebele, R. C., Lieb, S., Gianni, D., Voss, T., Garin‐Chesa, P., Haslinger, C., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.244129 · Cited by 117
Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function
Schmidt, S. L., Tayob, N., Han, M. K., Zappala, C. J., Kervitsky, D. J., Murray, S., Wells, A. U., Brown, K. K., Martínez, F. J., & Flaherty, K. R. (2013) · CHEST Journal · doi:10.1378/chest.13-0844 · Cited by 112
Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity
Sato, S., Shinohara, S., Hayashi, S., Morizumi, S., Abe, S., Okazaki, H., Chen, Y., Goto, H., Aono, Y., Ogawa, H., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0654-2 · Cited by 108
Doyle, T. J., Dhillon, N., Madan, R., Cabral, F., Fletcher, E. A., Koontz, D. C., Aggarwal, R., Osorio, J. C., Rosas, I. O., Oddis, C. V., et al. (2018) · The Journal of Rheumatology · doi:10.3899/jrheum.170541 · Cited by 102
Redente, E. F., Aguilar, M., Black, B. P., Edelman, B., Bahadur, A. N., Humphries, S. M., Lynch, D. A., Wollin, L., & Riches, D. W. H. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00304.2017 · Cited by 95
Self-citationHome monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis
Johannson, K. A., Vittinghoff, E., Morisset, J., Lee, J. S., Balmes, J. R., & Collard, H. R. (2017) · European Respiratory Journal · doi:10.1183/13993003.02406-2016 · Cited by 92
Unclassifiable interstitial lung diseases: Clinical characteristics and survival
Hyldgaard, C., Bendstrup, E. M., Wells, A. U., & Hilberg, O. (2016) · Respirology · doi:10.1111/resp.12931 · Cited by 82
Distler, O., Brown, K. K., Distler, J. H. W., Assassi, S., Maher, T. M., Cottin, V., Varga, J., Coeck, C., Gahlemann, M., Sauter, W., et al. (2017) · PubMed · Cited by 74
Self-citationPrecision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martínez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 71
Sambataro, G., Sambataro, D., Torrisi, S. E., Vancheri, A., Pavone, M., Rosso, R., Schisano, M., Crimi, C., Pignataro, F. S., Fischer, A., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0139-2017 · Cited by 63
Self-citationMaher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina‐Molina, M., Axmann, J., Kirchgaessler, K.-U., & Cottin, V. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000289 · Cited by 59
Self-citationEnvironmental, Inhaled and Ingested Causes of Pulmonary Fibrosis
Khalil, N., Churg, A., Müller, N. L., & O'Connor, R. N. (2007) · Toxicologic Pathology · doi:10.1080/01926230601064787 · Cited by 56
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis
Hook, J. L., Arcasoy, S. M., Zemmel, D., Bartels, M. N., Kawut, S. M., & Lederer, D. J. (2011) · European Respiratory Journal · doi:10.1183/09031936.00108111 · Cited by 52
Sharp, C., Adamali, H. I., & Millar, A. B. (2017) · ERJ Open Research · doi:10.1183/23120541.00096-2016 · Cited by 41
Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model
Lee, H. Y., Hur, J., Kim, I. K., Kang, J. Y., Yoon, H. K., Lee, S. Y., Kwon, S. S., Kim, Y. K., & Rhee, C. K. (2017) · Experimental Lung Research · doi:10.1080/01902148.2017.1339141 · Cited by 40
Maher, T. M. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328363f4b7 · Cited by 35
Magnini, D., Montemurro, G., Iovene, B., Tagliaboschi, L., Gerardi, R. E., Greco, E. L., Bruni, T., Fabbrizzi, A., Lombardi, F., & Richeldi, L. (2017) · Respiration · doi:10.1159/000475780 · Cited by 26
Assessment and management of connective tissue disease-associated interstitial lung disease.
Fischer, A., & Chartrand, S. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 20
Self-citation
Cited by
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
Self-citationSpectrum of fibrotic lung diseases
Wijsenbeek, M., & Cottin, V. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2005230 · Cited by 736
Self-citationWells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Self-citationWijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
Wollin, L., Distler, J. H. W., Redente, E. F., Riches, D. W. H., Stowasser, S., Schlenker-Herceg, R., Maher, T. M., & Kolb, M. (2019) · European Respiratory Journal · doi:10.1183/13993003.00161-2019 · Cited by 296
Self-citation
Metadata
- Authors
- Cottin, V., Wollin, L., Fischer, A., Quaresma, M., Stowasser, S., & Harari, S.
- Venue
- European Respiratory Review
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-02-27
- Volume
- 28
- Issue
- 151
- Pages
- 180100
- ISSN
- 0905-9180 (ISSN-L)
- 1600-0617
- OpenAlex
- W2920766120
- Cited by
- 336
- References
- 77
- FWCI
- 24.38
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.